Bio-Techne Corp [TECH] stock is trading at $73.21, up 1.81%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TECH shares have gain 4.09% over the last week, with a monthly amount glided 0.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, February 2024, BIO-TECHNE DECLARES DIVIDEND. In a post published today on Yahoo Finance, Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2023. The quarterly dividend will be payable February 26, 2024, to all common shareholders of record on February 12, 2024. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
From an analyst’s perspective:
Bio-Techne Corp [NASDAQ: TECH] stock has seen the most recent analyst activity on February 08, 2024, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $80. Previously, Stifel downgraded its rating to Hold on February 02, 2024, and kept the price target unchanged to $65. On December 07, 2023, UBS initiated with a Buy rating and assigned a price target of $80 on the stock. William Blair started tracking the stock assigning a Outperform rating. Wells Fargo upgraded its rating to a Equal Weight but $90 remained the price target by the analyst firm on January 10, 2023. Deutsche Bank started tracking with a Buy rating for this stock on December 14, 2022, and assigned it a price target of $100. In a note dated December 12, 2022, Citigroup upgraded an Buy rating on this stock and boosted its target price from $81.25 to $100.
Bio-Techne Corp [TECH] stock has fluctuated between $51.79 and $89.91 over the past year. Currently, Wall Street analysts expect the stock to reach $101.92 within the next 12 months. Bio-Techne Corp [NASDAQ: TECH] shares were valued at $73.21 at the most recent close of the market. An investor can expect a potential return of 39.22% based on the average TECH price forecast.
Analyzing the TECH fundamentals
Bio-Techne Corp [NASDAQ:TECH] reported sales of 1.15B for the trailing twelve months, which represents a growth of 0.37%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 72.05 points at the first support level, and at 70.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 73.89, and for the 2nd resistance point, it is at 74.56.
Bio-Techne Corp [TECH] reported earnings per share of $0.4 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.41/share, meaning a difference of -$0.01 and a surprise factor of -2.40%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.41 per share as compared to estimates of $0.43 per share, a difference of -$0.02 representing a surprise of -4.70%.
Ratios To Look Out For
For context, Bio-Techne Corp’s Current Ratio is 4.37. Also, the Quick Ratio is 3.03, while the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 10.05, the price to book ratio is 5.86 and price to earnings (TTM) ratio is 52.79.
Transactions by insiders
Recent insider trading involved Nusse Roeland, Director, that happened on Aug 30 when 8939.0 shares were sold. Chief Executive Officer, Kummeth Charles R. completed a deal on Jul 21 to sell 80000.0 shares. Meanwhile, Chief Executive Officer Kummeth Charles R. sold 322.0 shares on Jun 07.
